Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price traded down 5.7% during mid-day trading on Friday . The company traded as low as $17.16 and last traded at $17.25. 88,059 shares traded hands during trading, a decline of 88% from the average session volume of 738,610 shares. The stock had previously closed at $18.29.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Mesoblast in a report on Thursday, August 29th. Piper Sandler upped their price target on shares of Mesoblast from $11.00 to $15.00 and gave the stock an "overweight" rating in a research report on Thursday, December 19th. StockNews.com lowered shares of Mesoblast from a "hold" rating to a "sell" rating in a research note on Wednesday, September 4th. Jefferies Financial Group lowered Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday. Finally, Maxim Group upgraded Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $13.50.
Check Out Our Latest Research Report on MESO
Mesoblast Trading Down 4.2 %
The company's 50 day moving average price is $11.09 and its two-hundred day moving average price is $8.57. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of MESO. Marshall Wace LLP acquired a new stake in shares of Mesoblast in the second quarter valued at approximately $562,000. XY Capital Ltd purchased a new stake in Mesoblast in the 3rd quarter valued at $244,000. Jane Street Group LLC grew its holdings in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company's stock valued at $695,000 after buying an additional 26,959 shares in the last quarter. Creative Planning acquired a new stake in shares of Mesoblast in the 3rd quarter worth $147,000. Finally, XTX Topco Ltd purchased a new position in shares of Mesoblast during the 2nd quarter worth $103,000. 1.43% of the stock is owned by hedge funds and other institutional investors.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Recommended Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
